🟠 Amgen continues to defend its denosumab franchise, delaying biosimilar competition in the U.S. market. 
#glp1 #obesity #weightloss $LLY #Zepbound #biopharma #ozempic $NVO $vktx $zeal $tern $alt @FDA
#glp1 #obesity #weightloss #LLY #Zepbound #biopharma #ozempic #NVO #vktx #zeal #tern #alt